



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/445,919	03/16/2000	JOHAN STJERN SCHANTZ	10806-106	1522
24256	7590	06/02/2004	EXAMINER	
			FAY, ZOHREH A	
		ART UNIT	PAPER NUMBER	
		1614		
DATE MAILED: 06/02/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.  
DINSMORE & SHOHL, LLP  
1900 CHEMED CENTER  
255 EAST FIFTH STREET  
CINCINNATI, OH 45202

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/445,919	STJERN SCHANTZ ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Zohreh Fay	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM

#### THE MAILING DATE OF THIS COMMUNICATION.

THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_.
- 2a) This action is **FINAL**.
- 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 4, 5, 7-11 and 18-23 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_ is/are allowed.
- 6) Claim(s) 4, 5, 7-11 and 18-23 is/are rejected.
- 7) Claim(s) \_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
  - 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_.

- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_.

Claims 4, 5, 7-11 and 18-23 are presented for examination.

The final rejection of is hereby withdrawn.

Claim 4 is rejected under 35 U.S.C. 102 (b) as being anticipated by the Chemical Abstract 87:63008 for the reasons set forth on page 2 of the office action of February 5, 2003.

Claims 5, 7-11 and 18-23 are rejected under 35 U.S.C. 102(b) as being anticipated by Stjernschantz et al. for the reasons set forth on page 2 of the office action of February 5, 2003 and the following reasons for claims 22 and 23.

Stjernschantz et al. Teach the use of the claimed compounds for the treatment of glaucoma. Applicant's claims are drawn to the use of the claimed compounds for the treatment of glaucoma with reducing melanogenesis. It is the examiner's position that it does not appear the claim language or limitation result in a manipulative difference in the method steps when compared to the prior art disclosure. See Bristol-Myers Squibb Company V. Ben Venue Laboratories 58, USPQ2nd 1508 (CAFC 2001). The mechanism of action does not have bearing on the patentability of the invention if the invention was already known or obvious. Mere recognition of latent properties in the prior art does not render non-obvious an otherwise known invention. In re Wiseman, 201 USPQ 658 (CCPA 1979). Granting a patent on the discovery of unknown but inherent function would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from the prior art. In re Baxter Travenol Labs, 21 USOQ2nd 1281 (Fed. Cir. 1991). See MPEP 2145.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Fay whose telephone number is (571) 272-0573. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (571) 272-0573. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Z.F



Claims 4, 5, 7-11 and 18-23 are presented for examination.

The final rejection of is hereby withdrawn.

Claim 4 is rejected under 35 U.S.C. 102 (b) as being anticipated by the Chemical Abstract 87:63008 for the reasons set forth on page 2 of the office action of February 5, 2003.

Claims 5, 7-11 and 18-23 are rejected under 35 U.S.C. 102(b) as being anticipated by Stjernschantz et al. for the reasons set forth on page 2 of the office action of February 5, 2003 and the following reasons for claims 22 and 23.

Stjernschantz et al. Teach the use of the claimed compounds for the treatment of glaucoma. Applicant's claims are drawn to the use of the claimed compounds for the treatment of glaucoma with reducing melanogenesis. It is the examiner's position that it does not appear the claim language or limitation result in a manipulative difference in the method steps when compared to the prior art disclosure. See Bristol-Myers Squibb Company V. Ben Venue Laboratories 58, USPQ2nd 1508 (CAFC 2001). The mechanism of action does not have bearing on the patentability of the invention if the invention was already known or obvious. Mere recognition of latent properties in the prior art does not render non-obvious an otherwise known invention. In re Wiseman, 201 USPQ 658 (CCPA 1979). Granting a patent on the discovery of unknown but inherent function would remove from the public that which is in the public domain by virtue of its inclusion in, or obviousness from the prior art. In re Baxter Travenol Labs, 21 USQ2nd 1281 (Fed. Cir. 1991). See MPEP 2145.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Fay whose telephone number is (571) 272-0573. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (571) 272-0573. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Z.F

A handwritten signature in black ink, appearing to read "Zohreh Fay".